Important: starts at 8:00 am Pacific Time Zone

Linn’s Legacy: Bright Retinoblastoma Future is NOW

At the end of this CME activity participants should be able to:

1. Design with the patient’s family and healthcare team, a personalized treatment plan for patients with retinoblastoma based on genetic and cancer staging.

2. Evaluate in comparison to current treatment protocols, the clinical trial data suggesting a “game changer” new retinoblastoma therapy.

3. Consider benefits and limitations of sharing point-of-care data with patients’ families and the scientific community, while ensuring patient privacy and confidentiality.

Microsoft Teams Information: Join Now

• Password: dMhium

• Access code: 246 283 483 594

Brenda L. Gallie, MD, FRCSC, CM, OOnt

Ophthalmologist at The Hospital for Sick Children

Pediatric Ocular Oncologist at Alberta Children’s Hospital

Professor at the University of Toronto